Dr. Mohamed ElSayed is a Research Fellow at Eli Lilly and Company. In his current role as the Oral Peptide Delivery Platform Leader, Dr. ElSayed has developed and executed an integrated strategy for discovery and development of novel oral peptides as disruptive therapies. He has built from the ground a cross-functional multisite team of talented scientists that delivers Lilly’s oral peptides portfolio. Prior to joining Lilly Biotechnology Organization, Dr. ElSayed was a tenured professor at the University of Michigan, Ann Arbor, where he established and led the Cellular Engineering and Nano-Therapeutics Laboratory. His research spanned multiple disciplines including biopharmaceutics, drug delivery, and material sciences with special emphasis on development of novel parenteral and oral formulations for small molecules, biologics, nucleic acids, and imaging agents. In addition, Dr. ElSayed has served as a technical consultant for multiple pharmaceutical and biotechnology companies on challenging drug development programs. Dr. ElSayed has +25 years of experience leading cross-functional technical teams in academia and the pharmaceutical industry focusing on drug product development in oncology, inflammation, and diabetes. He has published 4 patents, +170 research articles and conference proceedings, and delivered +50 invited talks in international conferences. Dr. ElSayed received his Ph.D. in Pharmaceutical Sciences from the University of Maryland and his B.Sc. of Pharmacy from the Cairo University, Egypt.